BenevolentAI Investor Day Presentation Deck
Target validation in colon tissue from ulcerative colitis patients
Inflamed colonic mucosa biopsies from UC patients
• Disease phenotype retained with high basal cytokine release
• Readouts: IL6 and IL8 - key mediators of UC pathology
Tissue samples treated with:
• Target-selective tool compound (BEN-3218)
• Positive controls - prednisolone and tofacitinib
Selective target inhibition showed comparable
reduction of IL-6 and IL-8 to the positive controls
Validated as a target with a novel
mechanism of action for ulcerative colitis
Endoscopic
Biopsy from UC patients
Colonic mucosa
organ culture and compound
treatment
IL-6(pg/ml)
20000
15000-
10000-
5000-
0
✓
DMSO Prednisolone Tofacitinib BEN-3218
IL-8(pg/ml)
30000
20000-
10000-
0
Inflammatory cytokine
measurement
L L
DMSO Prednisolone Tofacitinib BEN-3218
Benevolent 58View entire presentation